In vitro activity of commercial probiotic Lactobacillus strains against uropathogenic Escherichia coli.
-
Delley M
Nestec Ltd, Nestlé Research Center, PO Box 44, CH-1000 Lausanne 26, Switzerland.
-
Bruttin A
Nestec Ltd, Nestlé Research Center, PO Box 44, CH-1000 Lausanne 26, Switzerland.
-
Richard M
Nestec Ltd, Nestlé Research Center, PO Box 44, CH-1000 Lausanne 26, Switzerland.
-
Affolter M
Nestec Ltd, Nestlé Research Center, PO Box 44, CH-1000 Lausanne 26, Switzerland.
-
Rezzonico E
Nestec Ltd, Nestlé Research Center, PO Box 44, CH-1000 Lausanne 26, Switzerland.
-
Brück WM
Nestec Ltd, Nestlé Research Center, PO Box 44, CH-1000 Lausanne 26, Switzerland Institute of Life Technologies, University of Applied Sciences Western Switzerland, CH-1950 Sion, Switzerland wolfram.bruck@hevs.ch.
Show more…
Published in:
- FEMS microbiology letters. - 2015
English
Urinary tract infection (UTI) is one of the most prevalent infections in humans. In ≥80% of cases, the etiologic agents are strains of uropathogenic Escherichia coli (UPEC), which commonly reside in the gastrointestinal tract. Lactobacilli have been shown to prevent UTI reoccurrence by restoring the urogenital microbiota when administered vaginally or orally. The goal of this study was to determine if commercial probiotic Lactobacillus spp. reduce or clear UPEC in vitro. Results show that it is likely that lactobacilli may, in addition to restoring a healthy urogenital microbiota through acidification of their environment, also displace adhering UPEC and cause a reduction of infection.
-
Language
-
-
Open access status
-
bronze
-
Identifiers
-
-
Persistent URL
-
https://folia.unifr.ch/global/documents/13782
Statistics
Document views: 14
File downloads: